New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy

xlomafota13 shared this article with you from Inoreader New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy Via Association française pour l'étude du cancer Bull Cancer. 2022 Jan 27:S0007-4551(22)00017-0. doi: 10.1016/j.bulcan.2022.01.002. Online ahead of print. NO ABSTRACT PMID:35094842 | DOI:10.1016/j.bulcan.2022.01.002 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.